purine nucleotide interconversions Inhibitors
1 drugsAbout purine nucleotide interconversions
Purine nucleotide interconversions are a network of biochemical reactions crucial for synthesizing and balancing purine nucleotides like ATP and GTP. These interconversions are essential for DNA/RNA synthesis, energy metabolism, and signaling pathways, impacting cell function.
Disrupting purine nucleotide interconversions can inhibit cell growth, making them attractive oncology targets. Currently, there is no genetic evidence directly linking this target to specific diseases.
Mercaptopurine, a small molecule approved in 2004, targets this pathway for oncology indications. Viatris is the sole company with an approved drug in this area.
Top purine nucleotide interconversions Drugs
Viatris is the only company with an approved drug targeting purine nucleotide interconversions.
Low competition suggests easier market entry but also unproven commercial viability.
purine nucleotide interconversions Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets purine nucleotide interconversions, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel approaches.
purine nucleotide interconversions Clinical Trials 87 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on purine nucleotide interconversions. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 16 | 5 | 2 | 9 | 71% |
| Phase 2 | 44 | 12 | 7 | 25 | 63% |
| Phase 3 | 23 | 10 | 0 | 13 | 100% |
| Phase 4 | 4 | 4 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
purine nucleotide interconversions Drug Approval Timeline (2004 - 2004)
The first and only drug, mercaptopurine, was approved in 2004.
The lack of recent approvals indicates potential target saturation or development challenges.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 39 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on purine nucleotide interconversions. A trial counts if an approved drug acting on purine nucleotide interconversions is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.